David Mauney

David Mauney is an experienced executive in the life sciences industry, currently serving as Managing Director at Koch Disruptive Technologies since February 2021. Prior roles include Operating Partner at Flagship Pioneering, President at Ziopharm Oncology, Managing Director at Harvest Capital Strategies, and Co-Founder and Managing Director of De Novo Ventures. At Ziopharm Oncology, David Mauney was instrumental in securing over $180 million in funding and restructuring key contracts, significantly improving the company’s financial standing. David Mauney holds an MD from the Geisel School of Medicine at Dartmouth and a BA from Duke University.